for acquired aphasia, but also, and often concomitantly, for other dysfunctions, such as severe behavioral disturbances, apraxia, and negative myoclonus. 15 Idiopathic cases and patients with benign childhood epilepsies associated with the ESES/CSWSS syndrome have been published. [17] [18] [19] The syndrome may occur in children with organic brain lesions, such as unilateral polymicrogyria (PMG), hydrocephalus, and thalamic lesions. 13, [20] [21] [22] [23] [24] [25] Treatment of the ESES/CSWSS syndrome has frequently been disappointing. Classic and new AEDs have been switched to benzodiazepines and ethosuximide. 17 An association of valproic acid and ethosuximide is still favored by different groups. 17, 19, 23 Sulthiame and levetiracetam have also been used. [26] [27] [28] [29] In refractory cases, therapeutic alternatives such as corticosteroids, gamma-globulins, the ketogenic diet, and surgery have been tried. 30, 31 There have been numerous descriptions of patients with unilateral ESES/CSWSS, as isolated in a larger series or sometimes compared to patients with bilateral ESES/CSWSS. 3, 4, 6, 13, 20, 27, [32] [33] [34] [35] [36] [37] However, they were not included in a well-designed methodological study analyzing only patients with unilateral ESES/CSWSS.
The aim of this study was to describe the electroclinical features, etiology, treatment, and prognosis of 21 patients with the hemi-ESES/CSWSS syndrome.
Methods
We conducted a retrospective, descriptive study of 21 consecutive patients with hemi-ESES/CSWSS syndrome followed between 1997 and 2012. All of them met the following inclusion criteria: (1) Onset with focal or apparently generalized seizures and focal EEG discharges; (2) Further appearance of atypical absences, and myoclonic, atonic (with or without epileptic falls), and/or generalized seizures; (3) Cognitive impairment and/or behavioral disturbances related to the hemi-ESES/CSWSS period; (4) Hemi-ESES/CSWSS occurring in more than 85% of non-REM sleep, at onset and during the ESES/CSWSS period. 2, 5 Patients who started with diffuse ESES/CSWSS and then evolved into hemi-ESES/ CSWSS were excluded. Patients with other epileptic encephalopathies (e.g. LandauKleffner syndrome, myoclonic astatic epilepsy with cognitive deterioration, and Lennox-Gastaut syndrome) and focal epilepsies with secondary bilateral synchronies not fulfilling the criteria for the hemi-ESES/CSWSS syndrome were also excluded.
In this study all patients underwent at least three prolonged sleep EEGs (more than one hour), and 12 of these 21 patients underwent all-night video-EEG in addition to the routine EEG recordings. The spike-wave index (SWI) on the non-REM sleep EEG during the hemi-ESES/CSWSS period was visually calculated based on the total number of spike-waves per unit of time or based on the information provided by the epileptologist in the clinical charts. Nevertheless, the fact that different epileptologists may have used different methods for calculation of the SWI based on different reports in the literature 2,5 may have caused a certain heterogeneity in the results. The term ESES/CSWSS used here includes both the EEG pattern and the clinical features. Brain magnetic resonance imaging (MRI) was obtained in all patients. Prolonged sleep EEGs were repeated two or more times per year. Data on school achievements and neuropsychological evaluations (Terman-Merrill or WISC III or IV) were repeatedly obtained during the follow-up of 2 to 15 years. In the absence of formal neuropsychological tests, based on the obtained information the degree of cognitive changes was evaluated according to clinical judgment in seven patients.
The onset and the resolution of the hemi-ESES/CSWSS phase were defined as the time of onset of cognitive impairment and behavioral abnormalities and the time of significant functional improvement which coincided in all cases with the time of the onset and offset of the pattern on the EEG. 38, 39 Biochemical controls, urine analysis, and plasma levels of classic AEDs were studied. The AEDs before and during the hemi-ESES/CSWSS phase were analyzed, as well as other treatment options such as corticosteroids, gamma-globulins, the ketogenic diet, and surgical treatments during the hemi-ESES/CSWSS period.
Determination of efficacy of the AED treatment was based on electroclinical criteria. Response of EEG abnormalities was graded as a normal recording, a more than 75% improvement of the SWI, a more than 50% improvement of the SWI, a more than 30% improvement of the SWI, focalization of the continuous generalized paroxysms, and no response. The percentages of improvement of SWI were related to the baseline SWI, e.g., a 50% improvement meant a decrease from 80% to 30%. Clinical response was considered as the decrease of cognitive and behavioral disturbances. The clinical response was graded as complete disappearance of clinical manifestations observed during the hemi-ESES/ CSWSS phase, and clinical improvement of more than 75%, of more than 50%, or of more than 30%. It was a rough estimation of severity based on the clinical data (Figs. 1-3) 
Results

General characteristics
A total of 21 children (14 boys and 7 girls) with the hemi-ESES/ CSWSS syndrome were identified between March 1997 and April 2010 at the Garrahan Hospital of Buenos Aires.
Regarding probable etiology, 11 children had PMG, and four presented with shunted hydrocephalus, three had porencephalic lesions associated with PMG, and three had a thalamic lesion. PMG was localized in the frontotemporal lobes in seven patients, in the parietooccipital lobes in two, and in the whole hemisphere in two other patients. The brain magnetic resonance imaging showed unilateral involvement in all cases except in three patients with thalamic lesions and one with hydrocephalus. From a syndromic point of view, all patients had cerebral palsy, 17 of which presented with hemiparesis and four with quadriparesis. Mental retardation was mild in 10, moderate in eight, and severe in three patients; six of these children had had behavioral disturbances before the onset of the hemi-ESES/CSWSS.
One patient had a positive family history of epilepsy and one of febrile seizures. Two patients had personal antecedents of febrile seizures, two patients had antecedents of West syndrome, and two of neonatal seizures.
Seizures and EEG findings before the onset of hemi-ESES/CSWSS
All children had experienced focal motor seizures before the onset of hemi-ESES/CSWSS. The seizures were associated with loss of awareness in five (24%). Three patients (14.5%) had had focal status epilepticus, 10 (47.5%) had had focal seizures with secondary generalization, and four (19%) had had apparently generalized seizures. Atypical absences were found in six patients (28.5%). Tonic seizures were not registered. Eight patients (38%) only had had seizures during the sleep, 10 (48%) only had had seizures while awake, and five (28.5%) had had seizures during sleep and while awake.
The current median age of the patients is 12 years. The median age at onset of structural focal epilepsy was 2.3 years. Median time elapsed between the first focal seizure and the onset of the hemi-ESES/CSWSS syndrome was 4 years.
Before hemi-ESES/CSWSS onset, the awake EEG recordings showed focal epileptiform abnormalities in 15 patients (70.5%) that were multifocal in nine (43%) and focal, associated with generalized paroxysms in three patients (14.5%). In this period, the focal spikes became more frequent on the sleep EEG recordings. Multifocal spikes were observed in 14 patients (66.5%) during sleep. Asymmetric baseline EEG activity was found in 15 (70.5%) cases.
In the phase immediately previous to hemi-ESES/CSWSS onset, a considerable increase of the interictal focal abnormalities was observed both during wakefulness and sleep predominantly in one hemisphere and in the anterior regions. 
Clinical features and EEG findings in the hemi-ESES/CSWSS syndrome phase
The median age at onset of the hemi-ESES/CSWSS syndrome was 6 years. The mean duration of ESES/CSWSS was 16 months (range, 6-36 months).
Fifteen (71.5%) of the 21 patients continued having seizures during the hemi-ESES/CSWSS period. Thirteen (61.5%) of them had more severe seizures. Nineteen patients (90.5%) of 21 also presented with new types of seizure during the hemi-ESES/CSWSS phase. These seizures were negative myoclonus in 14 patients (73.5%), positive myoclonus in 9 (47.5%), and absences in 11 (58%). Ten patients had motor impairment secondary to negative myoclonus and five had motor speech impairment.
When the children deteriorated, the following cognitive disturbances were observed: Attention deficit hyperactivity disorder in seven (33.5%), language deterioration (nonverbal agnosia) in five patients (24%), aggressiveness in six (28.4%), memory deficit in four patients (19%), impaired temporospatial orientation in four patients (19%), and loss of bladder control in three patients (14.3%). Baseline cognitive status was affected in 16 patients (76.2%). The features of the new cognitive involvement were fundamentally different from those of baseline cognitive function before the onset of the hemi-ESES/CSWSS period.
During the hemi-ESES/CSWSS phase, the awake EEG recording showed more frequent focal abnormalities, multifocal spikes, and isolated bilateral spikes and waves at 2-3 Hz, predominantly in the anterior regions. Additionally to the hemi-ESES/CSWSS, the sleep EEG recordings showed focal epileptic activity in nine patients (42.8%), bilateral epileptic activity in four patients (19%), and both focal and diffuse epileptic abnormalities in five cases (24%). In three patients (14.3%) the hemi-ESES/CSWSS recurred, twice in one patient and three times in two. Table 1 shows the general features, seizures, and EEG findings before and during the hemi-ESES/CSWSS period.
Treatment
Outcome according to the clinical criteria to evaluate response was: (a) Seizure freedom and repeated sleep EEGs showing disappearance of the hemi-ESES/CSWSS in eight patients (38%), of whom the syndrome was secondary to PMG in six, to hydrocephalus in one, to a porencephalic cyst associated with PMG in one, (b) significant reduction in seizure frequency (more than 75%), and improvement of more than 75% of the SWI in three patients (14.3%), (c) a 50-74% seizure reduction, and improvement of more than 50% of the SWI in two patients, (d) a 30-49% seizure reduction, and improvement of more than 30% of the SWI in one, and (e) no response in seven patients.
During the hemi-ESES/CSWSS phase a negative response was found to the following AEDs: Valproic acid in six patients, oxcarbazepine in five patients, lamotrigine in four patients, topiramate in four patients, phenobarbital in four patients, primidone in three patients, carbamazepine in three patients, clonazepam in one patient, levetiracetam in four patients, ethosuximide in two patients, and sulthiame in two other patients. Most of these AEDs were prescribed previous to consulting our department. All these AEDs except ethosuximide, clobazam, sulthiame, and clonazepam, worsened the electroclinical features of the hemi-ESES/ CSWSS in the majority of patients. A switch of these AEDs to ethosuximide, clobazam, and sulthiame, may be the first treatment step to significantly improve the electroclinical pattern.
The positive response that was seen using the different AEDs alone or in combination, and other treatment options was the following: clobazam and ethosuximide in two patients, clobazam and sulthiame in two patients, ethosuximide and valproic acid in two patients, ethosuximide and sulthiame in two patients, ethosuximide, clobazam and sulthiame in one patient, corticosteroids and valproic acid in two patients, corticosteroids and sulthiame in three patients, and corticosteroids, the ketogenic diet, clobazam and sulthiame in two patients. Successful epilepsy surgery was performed in three patients. In these latter three patients, based on the refractoriness of seizures after failure of different adequate antiepileptic schemes in high doses over a prolonged period of time added to a bad quality of life, a presurgical evaluation was done. All seizures were shown to arise from the affected hemisphere. Hemispherectomy was performed in two children and partial lesionectomy in the remaining patient.
A transient response was observed in five patients with the following AEDs: Sulthiame (one patient), valproic acid and 
Outcome
Average follow-up after hemi-ESES/CSWSS onset was 8 years (range, 2-15 years). At the last control, two patients have become seizure free and 12 have sporadic seizures. The EEG shows focal spikes in 14, multifocal spikes in seven, and bilateral asymmetric spikes in eight patients. Seizures are yearly in five, half-yearly in seven, and bi-monthly or monthly in nine. Seven patients have not responded well to treatment.
In our study the definitive control of the seizures and the normalization of the EEG depended on the etiology of the ESES/ CSWSS syndrome. The best results were obtained in patients with unilateral PMG in whom the course was relatively benign. Hemi-ESES/CSWSS disappeared in most of them and they have only sporadic seizures. In the post hemi-ESES/CSWSS period the duration of EEG abnormalities was significantly longer in the patients with underlying hydrocephalus and thalamic lesions.
In patients who became seizure free and in those who had a seizure reduction of more than 75%, school performance and IQ have improved significantly and they have returned to baseline cognitive function. However, it should be noted that in some of these children with structural ESES/CSWSS, it is very difficult to evaluate the neuropsychological profile during the active period of the epilepsy, mainly in the ESES/CSWSS phase.
Discussion
Our study suggests that the hemi-ESES/CSWSS syndrome has electroclinical features compatible with an epileptic encephalopathy. Our group of patients may have similar electroclinical features to the classic form of the ESES/CSWSS syndrome, however this study did not yield robust data to support this hypothesis and further research is necessary. Unilateral PMG was the most commonly found lesion, and the second most common was hydrocephalus. It seems that continuous activation of paroxysmal activity during sleep in one hemisphere may cause neuropsychological dysfunction, and this finding appears to be similar to bilateral or diffuse ESES/CSWSS in determining neurological deterioration. Thus, the age-dependent epileptiform discharges in a particular period of sleep per se, regardless of their unilateral or bilateral distribution, may play a crucial role in developing cognitive deterioration.
The results of our study and others published corroborate that the electroclinical criteria for the ESES/CSWSS syndrome should be revised and that hemi-ESES/CSWSS should be included in the EEG criteria. Isolated patients with hemi-ESES/CSWSS have been reported in the literature 3, 4, 6, 13, 20, 27, [32] [33] [34] [35] [36] [37] and there also is an electroclinical series of patients with ESES in mainly one hemisphere. 35 The association of PMG, a porencephalic cyst, hydrocephalus, or a thalamic lesion and ESES/CSWSS or hemi-ESES/CSWSS has been described. [20] [21] [22] [23] [24] [40] [41] [42] Hemi-ESES/CSWSS was defined as ESES/ CSWSS limited to a single hemisphere and the authors found this phenomenon in children with idiopathic partial epilepsy in the ESES/CSWSS period or in the remission stage. 36, 37 Some of these patients may therefore be considered similar to the children in this series.
Intellectual deterioration was found in 16 of 21 of the patients in our series. Other cognitive alterations, such as aggressiveness, hyperkinetic behavior, attention deficit hyperactivity disorder, expressive language disturbances, and learning difficulties were also observed. Similar cognitive dysfunctions, psychotic and autistic behavior, and behavioral disturbances have previously been reported. 43, 44 Ten patients in our series had motor impairment secondary to negative myoclonus and five had motor speech impairment. Motor impairment, such as pseudoataxia and even loss of independent gait, worsening of a unilateral deficit, fine motor clumsiness with distorted handwriting, dyspraxia, and dystonia have been described associated with the ESES/CSWSS syndrome. 2, 45 The EEG showed high-frequency oscillations that may affect normal brain functions in children with ESES/CSWSS. 46 These findings may explain the inhibition or involvement of the nonaffected contralateral hemisphere also participating in the cognitive and behavioral disturbances.
There are reports of children with structural or idiopathic focal epilepsies in which classic antiepileptic drugs, such as carbamazepine, oxcarbazepine, phenobarbital, or phenytoin, induced electrical status epilepticus during slow sleep; these should be avoided. 17, 47 Valproic acid, lamotrigine, and topiramate, have also been reported. 17 Levetiracetam has been involved in sporadic cases, 48 and the effect of levetiracetam on focal nocturnal epileptiform activity during sleep has been described in a placebo-controlled double-blind cross-over study. 49 To our knowledge, either in our series of patients or in other series of patients published 4, 17, 27, 28 this phenomenon has not been observed in patients receiving clobazam, ethosuximide, or sulthiame. The question is if the initial use of these AEDs before onset of unilateral or diffuse ESES may avoid the evolution into this particular electroclinical phenomenon. According to the pharmacological treatment described in the management of the ESES/CSWSS syndrome, some important issues should be taken into account. In the first place, it is crucial to revise the best AEDs to introduce in the pre-ESES/CSWSS phase. In patients with unilateral PMG, which is very frequently associated with ESES/CSWSS or hemi-ESES/CSWSS, or in patients with hydrocephalus associated with ESES/CSWSS or hemi-ESES/CSWSS, the choice of AEDs in the pre-ESES/CSWSS phase should be seriously reconsidered. Second, once the ESES/CSWSS or hemi-ESES/CSWSS period has started, the offending AEDs should be changed to clobazam, ethosuximide, or sulthiame, alone or in combination. The association of valproic acid and ethosuximide may be an alternative treatment option. In children who do not respond to AED therapy, corticosteroids should be considered early. 17, 19, 31 In refractory cases, the ketogenic diet and surgical treatment should also be considered. 17, 30, 50, 51 As our study demonstrates that patients with focal or unilateral ESES/CSWSS syndrome frequently have a unilateral cerebral lesion, we believe that pharmacologic treatment should be started as soon as possible, to timely consider surgery in refractory cases after failure of different adequate antiepileptic schemes in high doses over a prolonged period of time and after performing a thorough evaluation of each individual child.
Conclusions
Our study suggests that the hemi-ESES/CSWSS syndrome has electroclinical features compatible with an epileptic encephalopathy. It may be a variant of the ESES/CSWSS syndrome rather than a distinctive epileptic syndrome.
Unilateral polymicrogyria was the most commonly found lesion. The prognosis of these patients with a malformation of cortical development is relatively benign and thus adequate management may avoid cognitive deterioration and surgical intervention.
Most of the patients had cognitive deterioration. Cognitive recovery was observed in the drug responders who returned to baseline cognitive development, whereas in the drug nonresponders cognition continued to deteriorate.
In this series of patients, we recommend treatment with clobazam, ethosuximide, and sulthiame, alone or in combination. In refractory cases, high-dose corticosteroids may be administered. Although the number of patients in this study is too low to draw definite conclusions, we consider that in children with hemi-ESES/ CSWSS secondary to a unilateral lesion, surgery should be considered.
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